Healio - Industry News
Gilead announces continued focus on HBV, HCV, NASH
July 26, 2017
During an earnings conference call today, executives from Gilead Sciences disclosed second quarter earnings and projected pipeline goals with a focus on the company’s hepatitis B, hepatitis C and nonalcoholic steatohepatitis treatments.
Gilead's educational campaign boosted HCV diagnosis rates for baby boomersJuly 26, 2017
During an earnings conference call today, executives from Gilead Sciences disclosed second quarter earnings and projected pipeline goals with a focus on the company’s hepatitis B, hepatitis C and nonalcoholic steatohepatitis treatments.
Jaimy Lee
Executives at Gilead Sciences told investors Wednesday that an unbranded campaign encouraging baby boomers to get tested for hepatitis C helped boost screening and diagnosis numbers, which in turn upped sales of its HCV therapies.
Gilead reported that its HCV franchise generated sales of $1.9 billion in the second quarter of 2017, down 17% from the same quarter in 2016. But sales increased over the first quarter of the year, driven partly by patient starts (the initiation of an HCV therapy regimen), according to Mizuho Securities analyst Salim Syed.
Continue reading...
No comments:
Post a Comment